EXAMINER

Page 1 of 3 Atty. Docket No. Form PTO-1449 **U.S. Department of Commerce** Serial No. Patent and Trademark Office 67705/JPW/GJG/MML 10/772:938 Applicants: Eran Blaugrund et al. INFORMATION DISCLOSURE CITATION Filing Date (Use several sheets if necessary) November 13, 2003 U.S. PATENT DOCUMENTS Examiner Document Number Class Subclass Date Name Filing Date Initial if Appropriate Youdim, et al. 2/7/95 9/26/95 Youdim, et al.; 10/10/95 Youdim,et al.; 9/16/97 Youdim, et al.; 11/19/96 Youdim, et al.; 7/2/96 Youdim, et al.; 2/4/97 Youdim, et al.; 7/28/98 Youdim, et al.; 5/21/96 Youdim, et al.; 4/6/99 Youdim, et al.; 4/28/98 O Youdim, et al.; 2/7/95 Youdim, et al.; 20 04 00 10 1/15/04 Blaugrund et al.; FOREIGN PATENT DOCUMENTS Translation Document Number Date Country Class Subclass -Yes No 9/4/2003 WO 20 03 07 2 0 5 PCT; WO 20 04 04 5 6/3/04 PCT: OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bensimon G, et al., (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med., 330(9):585-91; Bentué-Ferrer D, et al., (1996) Monoamine Oxidase B Inhibitors. CNS Drugs., 6(3):217-36: Doble A. (1996) The pharmacology and mechanism of action riluzole. Neurology, 47 (Suppl. 1):S233-41; Eliash S, et al. (2001) "Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J. Neural Transm., 108:909-23; Ferrante RJ, et al., (1997) Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann. Neurol., 42:326-34; "Guidance for Industry: In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling," U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), November 1999; Gurney ME, et al., (1994) Motor neuron degeneration in mice that express a human superoxide dismutase mutation. Science, 264:1772-5;

DATE CONSIDERED

conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER: Injustri if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in

Applicants: Eran Blaugrund et al.

14/12958

Serial No.: 10/712,958 Filed: November 13, 2003

Exhibit A

5/20/08

11/13/2001

Form PTO-	PTO-1449 U.S. Department of Commerce PE												ochet No. PH/GJG/ALH	Serial No. 10/712,958		
									OSURE CITA		App al.	lica	its: Eran Bla	ugrund	<b>st</b>	
<del></del>		(Use several sheets if necessary) MAY 3 1 7007										Filing Date November 13, 2003			group	
									U.S. 1	PATENT BOSINES						
Examiner Initial		Document Number							Date	Name	Cla	88	Subclass	Filing Date if Appropriate		
2	1	3	5	ī	3	2	4	Þ	5/19/70	Gittos et al.			7			
7	2	5	4	8	6	5	4	1	1/23/96	Sterling et al.			1/			
1	3	6	ī	2	6	9	6	8	10/2/09	Peskin et al.	<del>                                     </del>		/	<del> </del>	<del>                                     </del>	
	4	6	2	7	7	8	8	ळ	8/21/01	Levy et al.	†		f		-	
	5	6	6	3	0	5	i	4	10/7/03	Youdim et al.	+	$\overline{}$	<del></del>	<del>                                     </del>	<del> </del>	
	5	6	5	3	5	6	6	7	10/21/03	Thomas	+	$\overline{}$	·	<del> </del>		
	7	6	9	_	-	o o	-	6-	10/18/03	Youdim et al. 10/18/800	15	+	<del>                                     </del>	+	<del> </del>	
	₽ 3	20			52	_	4	•—	3/18/04	Lerner et al.	1	1		<del>                                     </del>	1	
	9	20	05	00	93	8	3	þ	5/5/05	Youdim et al.		T		1		
	10	20		_	18	9	5	_	1/26/06	Lerner et al.						
	11	20	06		_	-	8	<u>B</u>	5/4/06	Youdim et al.						
	12	20	06	•	88	+	8	1	8/24/06	Peskin	1-1			$\downarrow$	·	
<u> </u>	13	11	-	9	5	7	2	6	11/10/06	Youdim et al.	4-4			<b></b>	<u> </u>	
_/_	14	11	6	0 .	0	5	6	1	11/15/06	Frenkel et al.	١ ١				<u> </u>	
													<del></del>			
	1	т —							T	PATENT DOCUMENTS	<del></del>			<del></del>		
		Document Number Date							Date	Country	CI	886	Subclass	L.,		
			1											Translation		
<del></del>	-	┢	Te	7.	6	Īź.	I.	<u></u>	7/12/05	ner	-			Yes	No	
<u>/</u>		9	5	ļ	-	6		7_	7/13/95	PCT	4		7			
1	16	9	6	<u> </u>	7_	1		9	11/28/96	PCT	1	·				
	17	9	7	<u> </u>	2	5	8	3	4/10/97	PCT						
l	18	9	8	þ	2	1	5	2	1/22/98	PCT				1		
	19	20	06	05	7	9	1.	2	6/1/06	PCT	Т		1			
7	20	0	4	3	6	4	9	2	6/8/94	PCT		$\overline{}$				
ラブ	21	0	5	3	8	ī	3	4	4/21/93	PCT	1	1			†	
	-	٠			THE	ED	DDI		ADT /Includ	·		4 8	er Fra l	1	<u> </u>	
<del>,</del> Z_	22	OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)  Finberg et al., (1981) "Selective Irreversible Propargy! Derivative Inhibitors of Monoamine Oxidase (MAO) without the														
7	23	Fint	Cheese Effect" Chem. Abstracts 94:202499 Finberg and Youdim, (1985) "Modification of Blood Pressure and Nictitating Membrane Response to Sympathetic Amine by Selective Monoamine Oxidase Inhibitors" Brit. J. Pharmac. 541-546													
	24												2			
- 1	1	Finberg et al. (1985) "Modification of Blood Pressure and Nictitating Membrane Response to Sympathetic Amides by Selective Monoamide Oxidase Inhibitors, Types A and B, in the Cat" Chem. Abstracts 103:81618														
1	25	Mer	ıdlei	cz a	nd l	M.B	.H.	You	dim (1987) Br	it. J. Psychiat. 142:508-511	Circi		<u> </u>	<del></del>		
1										Chemistry 21:138-167						
4	27	You	dim	et a	1. (1	988	) Ha	ndb	ook of Experin	nental Pharmacology Vol. 9	0/1(19	988) C	hapter 3 Trendlenb	urg and W	einer, ed	
7										anidine are ineffective in Al						
XXXINER		<	_	_		_	?	•	DATE CON	SIDERED 8/	10/0	01				
						_				W / 1	<i>0 7</i> -	,				
XAMINER:	Ini	tia	کھول	7	efe	ren	ce	con	sidered. w	hether or not citationce and not considered	on is	in	conformance wi	th MDRD	609.	

Applicants: Eran Blaugrund et al. Serial No.: 10/712,958 Filed: November 13, 2003 Exhibit A

وس 120|08